Q-omics provides the consensus-scored C15orf65 profile across patient tissues and cancer cell-line models. C15orf65 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, C15orf65 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, C15orf65 RNA expression shows 18,286 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, and UVM as cancer lineages where C15orf65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C15orf65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C15orf65 survival associations across molecular data types. C15orf65 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C15orf65 RNA expression–survival associations across cancer types. High C15orf65 expression shows unfavorable associations in KICH, LGG and LUSC, but favorable associations in UCEC, KIRP and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for C15orf65 RNA expression.
This table summarizes C15orf65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for C15orf65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C15orf65 shows lower tumor expression in KICH, THCA, KIRC and LUSC and higher tumor expression in LIHC and BRCA. The KICH box plot shows higher C15orf65 RNA expression in normal versus tumor tissue (log2 FC = −2.124, t-test p < 0.001).
This table shows molecular features associated with C15orf65 in patient tissues and cancer cell lines. In patient samples, C15orf65 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C15orf65 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
